Treatment Effects of Vortioxetine on Cognitive Functions in Mild Alzheimer's Disease Patients with Depressive Symptoms: A 12 Month, Open-Label, Observational Study
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
BACKGROUND/OBJECTIVES: depressive symptoms are common in Alzheimer's disease(AD). Aim of the study was to investigate the efficacy of vortioxetine compared with other conventional antidepressants on cognitive functions in AD patients with depressive symptoms. DESIGN: Prospective, randomized, 12 month, parallel-group study. SETTING: All participants were evaluated on-site at Neurodegenerative Disorders Unit, ASP2 Caltanissetta(Italy). PARTICIPANTS: 108(71 female, 37 male) AD patients with depression(mean age 76.7 ± 4.3). INTERVENTION: Randomized subjects received vortioxetine, 15 mg/day(n=36) or other common antidepressants(n=72). MEASURES: Primary outcome was change from baseline in the MMSE; secondary outcomes were change in Attentive Matrices, Raven Coloured Progressive Matrices, Digit Span, HAM-D and Cornell scale. RESULTS: Statistically significant improvement vs. controls was observed for vortioxetine on most of the cognitive tests and showed significantly baseline-to-endpoint reduction in both HAM-D and Cornell total scores.The most commonly reported adverse events were nausea and headache for votioxetine; nausea in the control group. CONCLUSIONS: Vortioxetine had a beneficial effect on cognition and mood in elderly AD patients and was safe and well tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropsychiatric symptoms in Alzheimer's disease
Lyketsos, C. G., Carrillo, M. C., Ryan, J. M., Khachaturian, A. S., Trzepacz, P., Amatniek, J., Cedarbaum, J., Brashear, R., & Miller, D. S. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.05.2410 · Cited by 1,139
Sanchez, C., Asin, K. E., & Artigas, F. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.07.001 · Cited by 547
Katona, C., Hansen, T., & Olsen, C. K. (2012) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3283542457 · Cited by 445
McIntyre, R. S., Lophaven, S., & Olsen, C. K. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714000546 · Cited by 433
Mahableshwarkar, A. R., Zajecka, J., Jacobson, W., Chen, Y., & Keefe, R. S. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.52 · Cited by 307
Orgeta, V., Tabet, N., Nilforooshan, R., & Howard, R. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-161247 · Cited by 203
du Jardin, K. G., Jensen, J. B., Sanchez, C., & Pehrson, A. L. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.07.001 · Cited by 133
Moraros, J., Nwankwo, C., Patten, S. B., & Mousseau, D. D. (2017) · Depression and Anxiety · doi:10.1002/da.22584 · Cited by 105
Vieta, E., Sluth, L. B., & Olsen, C. K. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.11.053 · Cited by 72
Which cognitive domains are improved by treatment with vortioxetine?
Harrison, J. E., Lophaven, S., & Olsen, C. K. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw054 · Cited by 59
Cumulative Antidepressant Use and Risk of Dementia in a Prospective Cohort Study
Heath, L., Gray, S. L., Boudreau, D. M., Thummel, K., Edwards, K. L., Fullerton, S. M., Crane, P. K., & Larson, E. B. (2018) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15508 · Cited by 41
Cited by
Depression in Alzheimer’s Disease: Epidemiology, Mechanisms, and Treatment
Huang, Y.-Y., Gan, Y.-H., Yang, L., Cheng, W., & Yu, J.-T. (2024) · Biological Psychiatry · doi:10.1016/j.biopsych.2023.10.008 · Cited by 164
Vortioxetine for cognitive enhancement in major depression: From animal models to clinical research
Bennabi, D., Haffen, E., & Van Waes, V. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00771 · Cited by 75
“Interestingly, a recent RCT investigated the efficacy of vortioxetine on cognitive functions in Alzheimer disease patients with depressive symptoms and reported significant improvement in most of the cognitive tests applied (75).”
BackgroundHuang, I.-C., Chang, T.-S., Chen, C., & Sung, J.-Y. (2022) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyac054 · Cited by 41
“Vortioxetine can influence multiple cognitive domains, such as attention, orientation, executive function and concentration (Harrison et al., 2016; Bennabi et al., 2019; Cumbo et al., 2019).”
Background
Metadata
- Authors
- Cumbo, E., Cumbo, S., Torregrossa, S., & Migliore, D.
- Venue
- The Journal of Prevention of Alzheimer's Disease
- Publisher
- Elsevier BV
- Published
- 2019-07
- Volume
- 6
- Issue
- 3
- Pages
- 192-197
- ISSN
- 2274-5807 (ISSN-L)
- OpenAlex
- W2937407505
- Cited by
- 57
- References
- 11
- FWCI
- 3.34
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.